KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sarepta Therapeutics (SRPT) Other Non Operating Income (2016 - 2025)

Sarepta Therapeutics (SRPT) has 14 years of Other Non Operating Income data on record, last reported at $21.9 million in Q4 2024.

  • For Q4 2024, Other Non Operating Income rose 38.91% year-over-year to $21.9 million; the TTM value through Dec 2024 reached $42.7 million, up 29.16%, while the annual FY2024 figure was $42.7 million, 29.16% up from the prior year.
  • Other Non Operating Income reached $21.9 million in Q4 2024 per SRPT's latest filing, up from $14.3 million in the prior quarter.
  • Across five years, Other Non Operating Income topped out at $387.3 million in Q1 2023 and bottomed at -$357.7 million in Q2 2023.
  • Average Other Non Operating Income over 5 years is $6.3 million, with a median of $112000.0 recorded in 2020.
  • Peak YoY movement for Other Non Operating Income: plummeted 27076.56% in 2022, then surged 2343.27% in 2023.
  • A 5-year view of Other Non Operating Income shows it stood at $160000.0 in 2020, then skyrocketed by 113.75% to $342000.0 in 2021, then plummeted by 7986.26% to -$27.0 million in 2022, then skyrocketed by 158.38% to $15.7 million in 2023, then surged by 38.91% to $21.9 million in 2024.
  • Per Business Quant database, its latest 3 readings for Other Non Operating Income were $21.9 million in Q4 2024, $14.3 million in Q2 2024, and $6.5 million in Q1 2024.